Our patient cohort consisted of three AML patients with TP53 mutation (AML017, AML018 and AML306), one AML patient with TP53 wild type (AML023), and two patients with B-cell malignancies; one hairy cell leukemia (HCL089) and one chronic lymphocytic leukemia (CLL151). Here, TP53 is linked to B-cell chronic lymphocytic leukemia.